文献速递支持与姑息治疗

免疫检查点抑制剂与结核病:新背景下的旧疾

Immune checkpoint inhibitors and tuberculosis: an old disease in a new context.
PubMed 文献 · Lancet Oncol · 2020-01-01

本文讨论免疫检查点抑制剂治疗与结核病的关系,指出与抗TNFα治疗前常规筛查潜伏结核不同,ICI治疗前筛查并不常规。作者报告了70例转移性皮肤癌接受ICI治疗的结核筛查经验,基于结核与免疫系统相互作用,主张ICI治疗前筛查结核,并在考虑抗TNFα治疗严重irAE时使用筛查。呼吁在完全明确ICI对结核病理生理影响前保持警惕。

要点

  • ICI治疗前结核筛查不常规,但原发感染或潜伏结核再激活报告增多。
  • 抗TNFα治疗前筛查潜伏结核是常规,ICI治疗前则否。
  • 作者报告70例转移性皮肤癌ICI治疗患者的结核筛查经验。

核心结论

  • 应提高对ICI治疗期间结核病的警惕,直至其影响完全明确。
  • 主张ICI治疗前进行结核筛查,并在考虑抗TNFα治疗严重irAE时使用筛查。

研究设计与样本

  • 本文为综述/观点类文章,结合作者70例转移性皮肤癌接受ICI治疗的结核筛查经验进行论述。

主要发现

  • ICI治疗期间原发结核感染或潜伏结核再激活的报告增多。
  • ICI治疗前结核筛查不常规,而抗TNFα治疗前筛查潜伏结核是常规。

临床怎么用

  • ICI治疗前应考虑结核筛查。
  • 考虑抗TNFα治疗严重irAE时应使用结核筛查。
  • ICI治疗期间对结核保持警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis, the leading cause of infection-related death in developing regions, is a leading cause of morbidity and mortality worldwide. Screening for, and treatment of, latent Mycobacterium tuberculosis infection is routine before initiation of anti-tumour necrosis factor α (anti-TNFα) agents in the management of psoriasis, Crohn's disease, and rheumatoid arthritis. By contrast, screening for latent tuberculosis before immune checkpoint inhibitor treatment in cancer is not routine, despite the increasing number of reports of primary infection with M tuberculosis or reactivation of latent M tuberculosis infection during such treatment. We present our experience with M tuberculosis screening in 70 patients who underwent immune checkpoint inhibitor therapy for metastatic skin cancer. Based on our understanding of the interaction between M tuberculosis and the immune system, we present the argument for tuberculosis screening before immune checkpoint inhibitor therapy and its use when considering anti-TNFα treatment for severe immune-related adverse events. We call for increased vigilance during immune checkpoint inhibition until its effects on tuberculosis pathophysiology are fully ascertained.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Langan EA, Graetz V, Allerheiligen J, et al. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol. 2020. PMID: 31908308. doi:10.1016/S1470-2045(19)30674-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。